# Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents

Study · id `cardio:ct-nct07307235` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07307235](<https://clinicaltrials.gov/study/NCT07307235>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07307235

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1316 participants.

## Technical summary

Registry record NCT07307235. Randomized; no masking; primary purpose treatment. Start 2025-12-13 (actual); primary completion 2027-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1316 participants (planned count; ClinicalTrials.gov record NCT07307235, source copy `cardio:ctgov-nct07307235-2026-07-07`, retrieved 2026-10-26)
- Started: 2025-12-13 (actual) (ClinicalTrials.gov record NCT07307235, source copy `cardio:ctgov-nct07307235-2026-07-07`, retrieved 2026-10-26)
- Primary completion: 2027-06-30 (anticipated) (ClinicalTrials.gov record NCT07307235, source copy `cardio:ctgov-nct07307235-2026-07-07`, retrieved 2026-10-26)
- Completion: 2027-12-30 (anticipated) (ClinicalTrials.gov record NCT07307235, source copy `cardio:ctgov-nct07307235-2026-07-07`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07307235, source copy `cardio:ctgov-nct07307235-2026-07-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07307235-2026-07-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
- Condition: Type 2 Diabetes
- Intervention (Drug): iGlarLixi (insulin glargine/lixisenatide)
- Intervention (Drug): standard of care (basal insulin or premixed insulin, excluding any GLP-1 receptor agonist-containing drugs)
- Lead sponsor: Shanghai Zhongshan Hospital
- Lead sponsor class: OTHER
- Collaborator: Sanofi (China) Investment Co., Ltd
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Shanghai Zhongshan Hospital (`cardio:org-shanghai-zhongshan-hospital`)

## Provenance

Content hash: 8af87215261df9172d58858a40caa69d13bc71638d00735ce98965d57582fbad
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
